CORCEPT THERAPEUTICS Clinical Trials

Company details

Status: Public
HQ: 101 Redwood Shores Pkwy, Redwood City, California 94065, US
Founded: 1998
Employees: 756
Programs: 67
Drugs: 36
Patents: 120

Official website ↗ All projects Drug pipeline Patents News & analysis

Recent trial activity

8 updates

Latest clinical program signals indexed for CORCEPT THERAPEUTICS.

Trial registry

77 studies

2024-514079-17-00
CORT125134-452

Phase 3 active other

Endogenous Cushing Syndrome

CTIS ↗
2024-514080-25-00
CORT125134-556

Phase 3 active small_molecule

Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

CTIS ↗
2024-514082-19-00
CORT113176-652

Phase 2 active small_molecule

Amyotrophic Lateral Sclerosis

CTIS ↗
2024-517432-21-00
CORT125134-557

Phase 2 active small_molecule

Gynecological Cancers

CTIS ↗
NCT00105105
Mifepristone

Phase 2 terminated small_molecule

Alzheimer's Disease

CT.gov ↗
NCT00128479
mifepristone

Phase 3 completed small_molecule

Major Depressive Disorder

CT.gov ↗
NCT00128505
mifepristone

Phase 3 completed small_molecule

Major Depressive Disorder

CT.gov ↗
NCT00130676
mifepristone

Phase 3 completed small_molecule

Major Depressive Disorder

CT.gov ↗
NCT00146523
mifepristone

Phase 3 completed small_molecule

Major Depressive Disorder

CT.gov ↗
NCT00208156
Mifepristone

Phase 3 completed small_molecule

Depressive Disorder, Major

CT.gov ↗
NCT00455442
Mifepristone

Phase 2 completed small_molecule

Weight-Gain Prevention

CT.gov ↗
NCT00569582
mifepristone

Phase 3 completed small_molecule

Cushing's Syndrome

CT.gov ↗
NCT00637494
mifepristone

Phase 3 terminated small_molecule

Psychotic Depression

CT.gov ↗
NCT00698022
Risperidone

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT00752843
mifepristone + fluvastatin

Phase 1 completed small_molecule

Healthy Subjects

CT.gov ↗
NCT00936741
mifepristone

Phase 3 completed small_molecule

Cushing's Syndrome

CT.gov ↗
NCT01371565
mifepristone

Phase 3 terminated small_molecule

Cushing's Disease

CT.gov ↗
NCT01925092
mifepristone

Phase 3 terminated small_molecule

Cushing's Disease

CT.gov ↗
NCT02014337
Mifepristone and Eribulin in combination

Phase 1 completed small_molecule

Breast Cancer

CT.gov ↗
NCT02642939
Mifepristone

Phase 2 terminated small_molecule

Non-Small Cell Lung Cancer (NSCLC)

CT.gov ↗
NCT02762981
Relacorilant with nab-paclitaxel

Phase 2 completed small_molecule

Solid Tumors

CT.gov ↗
NCT02804750
CORT125134

Phase 2 completed small_molecule

Cushing's Syndrome

CT.gov ↗
NCT03067376
[14C]-CORT125134

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT03258372
Mifepristone

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT03259542
Mifepristone 300 MG

Phase 1 completed small_molecule

Drug Interaction Potentiation

CT.gov ↗
NCT03315338
CORT118335, 25 mg

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT03335956
CORT125281-600

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT03437941
Exicorilant

Phase 2 terminated small_molecule

Metastatic Castration-Resistant Prostate Cancer

CT.gov ↗
NCT03442621
Relacorilant Fasted

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT03457597
Midazolam hydrochloride

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT03508635
CORT125134

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT03512548
Relacorilant 350mg

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT03540836
Relacorilant (3x100 mg softgel capsules)

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT03604198
relacorilant

Phase 3 active small_molecule

Cushing Syndrome

CT.gov ↗
NCT03674814
Enzalutamide

Phase 1 completed small_molecule

Prostate Cancer

CT.gov ↗
NCT03697109
relacorilant

Phase 3 active small_molecule

Cushing Syndrome

CT.gov ↗
NCT03776812
Relacorilant

Phase 2 completed small_molecule

Recurrent Ovarian Cancer

CT.gov ↗
NCT03818256
Miricorilant

Phase 2 completed small_molecule

Antipsychotic-induced Weight Gain (AIWG)

CT.gov ↗
NCT03823703
Miricorilant

Phase 2 active small_molecule

Nonalcoholic Steatohepatitis (NASH)

CT.gov ↗
NCT03877562
Olanzapine

Phase 1 completed small_molecule

Antipsychotic-induced Weight Gain

CT.gov ↗
NCT03877952
14C-CORT125281

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT03878264
CORT118335 Oral

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT04249323
CORT113176 Lipid Capsule Formulation

Phase 1 completed small_molecule

Healthy Adults

CT.gov ↗
NCT04308590
Relacorilant

Phase 3 completed small_molecule

Hypercortisolism

CT.gov ↗
NCT04329949
Relacorilant, 100 mg and 25 mg

Phase 3 terminated small_molecule

Metastatic Pancreatic Ductal Adenocarcinoma

CT.gov ↗
NCT04373265
Relacorilant

Phase 1 completed small_molecule

Adrenocortical Carcinoma

CT.gov ↗
NCT04524403
Miricorlilant

Phase 2 completed small_molecule

Antipsychotic-induced Weight Gain (AIWG)

CT.gov ↗
NCT04588688
Mifepristone

Phase 2 terminated small_molecule

Central Adrenal Insufficiency

CT.gov ↗
NCT04672499
Miricorilant 300 mg tablets

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT04672512
CORT125329 lipid capsule formulation

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT04795479
Relacorilant

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT04990310
[14C]-CORT113176

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT04994743
CORT113176

Phase 1 completed small_molecule

Healthy Adults

CT.gov ↗
NCT05003713
CORT125236

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT05117489
Miricorilant 150 mg

Phase 1 completed small_molecule

Nonalcoholic Steatohepatitis (NASH)

CT.gov ↗
NCT05217758
mifepristone

Phase 3 completed small_molecule

Major Depressive Disorder

CT.gov ↗
NCT05257408
Nab-paclitaxel 80 mg/m^2

Phase 3 active small_molecule

Ovarian Neoplasm

CT.gov ↗
NCT05347979
Dabigatran Etexilate

Phase 1 completed small_molecule

Cushing Syndrome

CT.gov ↗
NCT05407324
Dazucorilant 300 mg

Phase 2 active small_molecule

Amyotrophic Lateral Sclerosis

CT.gov ↗
NCT05553470
Miricorilant

Phase 1 completed small_molecule

Non-alcoholic Steatohepatitis (NASH)

CT.gov ↗
NCT05712265
Miricorilant

Phase 1 completed small_molecule

Antipsychotic Induced Weight Gain

CT.gov ↗
NCT05772169
Mifepristone 300 MG [Korlym]

Approved completed small_molecule

Hypercortisolism

CT.gov ↗
NCT06094712
CORT125134

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT06094725
Relacorilant

Phase 1 completed small_molecule

Hepatic Impairment

CT.gov ↗
NCT06094738
Relacorilant under fasted conditions

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT06094790
CORT125134 150 mg

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT06099769
Enzalutamide

Phase 2 active small_molecule

Metastatic Breast Cancer

CT.gov ↗
NCT06108219
Miricorilant (Cohort A)

Phase 2 active small_molecule

Nonalcoholic Steatohepatitis (NASH)

CT.gov ↗
NCT06495944
Dazucorilant

Phase 1 completed small_molecule

Healthy Adults

CT.gov ↗
NCT06689254
Mifepristone 1200 mg daily

Phase 2 active small_molecule

Treatment-resistant PTSD

CT.gov ↗
NCT06906341
Relacorilant 150 mg once daily (QD)

Phase 2 active small_molecule

Ovarian Cancer

CT.gov ↗
NCT06928779
Dazucorilant

Phase 1 completed small_molecule

Hepatic Impairment

CT.gov ↗
NCT06947304
Miricorilant

Phase 2 active small_molecule

Nonalcoholic Steatohepatitis (NASH)

CT.gov ↗
NCT07240116
Miricorilant Treatment A

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT07259317
Relacorilant 150 mg once daily (QD)

Phase 2 active small_molecule

Adenocarcinoma

CT.gov ↗
NCT07276373
Nenocorilant 200 mg

Phase 2 active small_molecule

Neoplasms

CT.gov ↗
NCT07553663
Miricorilant

Phase 2 active small_molecule

Nonalcoholic Steatohepatitis (NASH)

CT.gov ↗

Recent trial activity

Trial registry

Stay Ahead in Pharma